SuperworthVera Therapeutics VERA
- Market cap
- $2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −16.8%
Vera Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $16.1M−18% | $20.8M−22% | $23.2M−8% | $29.3M+81% | $40.3M+150% | $33.3M+60% | $41.3M+78% | $58.2M+99% | $56.5M+40% | $59.3M+78% | $86M+108% | $60.1M+3% |
| SG&A | $5.7M+1% | $6.2M−10% | $7.9M+29% | $8M+40% | $9.5M+68% | $15.6M+149% | $15.9M+101% | $21.9M+173% | $27.5M+189% | $34.9M+124% | $39.1M+146% | $52.4M+139% |
| −$21.8M−14% | −$27M−20% | −$31.1M−1% | −$37.3M+70% | −$49.8M+129% | −$48.9M+81% | −$57.2M+84% | −$80.1M+115% | −$83.9M+69% | −$94.2M+93% | −$125.1M+119% | −$112.5M+40% | |
| Interest expense | $943K+542% | $1.1M+76% | $1.9M+118% | $1.9M+109% | $1.9M+105% | $1.9M+77% | $1.8M−6% | $1.9M−2% | $2M+1% | $1.9M+2% | $1.8M+2% | $1.8M−1% |
| Net income | −$20.1M−19% | −$25.7M−21% | −$28.4M−6% | −$33.7M+67% | −$46.6M+132% | −$43.4M+69% | −$51.7M+82% | −$76.5M+127% | −$80.3M+72% | −$91.1M+110% | −$121M+134% | −$109.5M+43% |
| −$0.45−51% | −$0.58−50% | −$0.56−30% | −$0.62+35% | −$0.85+89% | −$0.72+24% | −$0.81+45% | −$1.20+94% | −$1.26+48% | −$1.39+93% | −$1.69+109% | −$1.52+27% | |
| 44.4M+63% | 44.4M+60% | 51M+35% | 54.7M+24% | 54.9M+24% | 60.7M+37% | 63.7M+25% | 63.8M+17% | 63.8M+16% | 65.6M+8% | 71.5M+12% | 71.8M+13% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Vera Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VERAVera Therapeutics | $2B | n/m | n/a | n/m | n/m | n/m | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| Peer median | $1.6B | 14.1× | 17.9× | 1.8× | +6% | 10.9% |
More on Vera Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .